Your browser doesn't support javascript.
loading
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
Yuan, Yuan; Lee, Jin Sun; Yost, Susan E; Frankel, Paul H; Ruel, Christopher; Egelston, Colt A; Guo, Weihua; Padam, Simran; Tang, Aileen; Martinez, Norma; Schmolze, Daniel; Presant, Cary; Ebrahimi, Behnam; Yeon, Christina; Sedrak, Mina; Patel, Niki; Portnow, Jana; Lee, Peter; Mortimer, Joanne.
Afiliação
  • Yuan Y; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA. Electronic address: yuyuan@coh.org.
  • Lee JS; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Yost SE; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Frankel PH; Department of Biostatistics, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Ruel C; Department of Biostatistics, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Egelston CA; Department of Immune-Oncology, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Guo W; Department of Immune-Oncology, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Padam S; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Tang A; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Martinez N; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Schmolze D; Department of Pathology, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Presant C; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Ebrahimi B; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Yeon C; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Sedrak M; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Patel N; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Portnow J; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Lee P; Department of Immune-Oncology, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
  • Mortimer J; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Beckman Research Institute, Duarte, CA, USA.
Eur J Cancer ; 154: 11-20, 2021 09.
Article em En | MEDLINE | ID: mdl-34217908

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article